Page 9 - CIMA SCS Workbook November 2018 - Day 2 Tasks
P. 9

STRATEGIC MANAGEMENT (E3) - PRACTICE TASKS


                  EXERCISE 2


                  UPDATE
                  You are working at your desk late one morning when you receive the following email from Anton
                  Frind, Novak’s Director of Research:

                  TRIGGER


                  Email

                  To:        Senior Manager
                  From:      Anton Frind, Director of Research
                  Subject:   Investment in orphan drug and response to criticism

                  I have been forwarded a proposal from one of our senior research scientists; a copy is attached
                  for your information.

                  As we are all well aware, the topic of orphan drugs is the subject of much debate. Pharmaceutical
                  companies such as Novak and its competitors want to challenge continually the boundaries of
                  medical science, but we also have a responsibility to our shareholders to produce a return. I think
                  it is inevitable that some research on orphan drugs will always be discontinued simply on the
                  grounds of cost and limited potential revenue until governments intervene. I am conscious that
                  this matter will be on the agenda at the forthcoming summit of world leaders.

                  I need to respond to this proposal today but am tied up in other meetings – could you please set
                  out the benefits and risks of agreeing to the NX1 research project and provide a preliminary
                  conclusion?

                  Secondly, you might have heard that I and several other Board members have received
                  anonymous threats due to the company’s use of animal testing in its laboratories. I am afraid that
                  this is an occupational hazard; we must accept that the research we consider so vital does not sit
                  well with certain activists. I feel that Novak should make some public statement, as the wording in
                  the most recent threats has been troubling (company policy on threats to employee welfare is to
                  report all such matters to the police, and this has already been done).

                  Could you please advise on the possible ethical stances Novak might take in the face of claims that
                  the company is unethical in its behaviour towards testing on animals?

                  Many thanks


                  TASK

                  Prepare an email in response to Anton Frind’s requests        (Time allowed: 60 minutes)

                  (Refer to the reference materials overleaf)







                  KAPLAN PUBLISHING                                                                    25
   4   5   6   7   8   9   10   11   12   13   14